Recent progress of multiple myeloma: reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.01.005
- VernacularTitle:多发性骨髓瘤新进展:第57届美国血液学会年会报道
- Author:
Zhijian CAO
;
Jun MA
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Proteasome inhibitor;
Immunetherapy;
Immunomodulatory agents;
Histone deacetylase inhibitor;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(1):15-18
- CountryChina
- Language:Chinese
-
Abstract:
The diagnosis and treatment of multiple myeloma (MM) have make remarkable progress, which were reviewed in the 57th American Society of Hematology (ASH) annual meeting. In this annual meeting, the effects of advanced proteasome inhibitor (PI), antibody, checkpoint blockade, immunomodulatory agent (IMiD), histone deacetylase (HDACI) and chimeric antigen receptor T-cell (CAR-T), and new diagnostic technologies were reported. The real point is to apply the best available diagnosis and therapy at this meeting. At present, regardless of advances, all of randomized clinical trials push to combined agents, and combined with hematopoietic stem cell transplantation, efficacy will be improved in further. So some professors also refered to 2015 year as 'the advance year of MM'.
